The FDA has expanded the approval of Repatha to reduce the risk of major adverse cardiovascular events in adults at increased risk for these events.

The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...